A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Public ClinicalTrials.gov record NCT05070858. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How the study drugs work inside the body * How much of the study drugs are in the blood at different times * Whether the body makes antibodies against pozelimab and cemdisiran (which could make the drugs less effective or could lead to side effects)
Study identification
- NCT ID
- NCT05070858
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 288 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2021 (Actual)
- Primary completion
- Jul 8, 2025 (Actual)
- Completion
- Nov 11, 2028 (Estimated)
- Last update posted
- Jul 8, 2026
2021 – 2028
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Neurology 2018 | Scottsdale | Arizona | 85251 | — |
| University of California Irvine | Irvine | California | 92697 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| Colorado Springs Neurological Associates | Colorado Springs | Colorado | 80907-5307 | — |
| SFM Clinical Research, LLC | Boca Raton | Florida | 33487 | — |
| Diverse Clinical Research | Miami | Florida | 33175 | — |
| Aqualane Clinical Research | Naples | Florida | 34105 | — |
| Neurological Services of Orlando | Orlando | Florida | 32806 | — |
| Medsol Clinical Research Center Inc | Port Charlotte | Florida | 33952 | — |
| University of South Florida Morsani Center for Advanced Healthcare | Tampa | Florida | 33612 | — |
| NorthShore University Health System | Glenview | Illinois | 60026-1301 | — |
| St. Elizabeth's Hospital | O'Fallon | Illinois | 62269 | — |
| Northwest Neurology Ltd. - Clinedge - PPDS | Rolling Meadows | Illinois | 60080 | — |
| Wayne State University School of Medicine | Detroit | Michigan | 48201 | — |
| Dayton Center for Neurological Disorders | Centerville | Ohio | 45459 | — |
| University of Cincinnati Gardner Neuroscience Institute | Cincinnati | Ohio | 45219 | — |
| Penn Medicine University City | Philadelphia | Pennsylvania | 19104 | — |
| National Neuromuscular Research Institute | Austin | Texas | 78759 | — |
| Nerve and Muscle Center of Texas | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05070858, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05070858 live on ClinicalTrials.gov.